Biotech
-
Seagen strengthens case for cancer drug as buyout rumors swirl
New study results support the potential use of its breast cancer medicine Tukysa, part of a wide-ranging alliance with rumored…
Read More » -
CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement
The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development…
Read More » -
In ‘unusual’ move, FDA to reconvene advisers for ALS drug review
The drug’s developer, Amylyx Pharmaceuticals, said the meeting is scheduled for Sept. 7 and experts will discuss additional data analyses conducted…
Read More » -
With $100M AstraZeneca deal, a biotech and its investors engineer another buyout
An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since…
Read More » -
10 clinical trials to watch in the second half of 2022
The biotech industry's downturn accelerated in the first half of the year. Important study readouts for Eisai, Gilead, Merck and…
Read More » -
Celldex, continuing comeback, adds to early promise for skin disease drug
New study results show the medicine appears as effective, or stronger, than standard care for chronic urticarias, a common condition that…
Read More » -
Crunching the numbers on the first half drought for biotech IPOs
Data compiled by BioPharma Dive show a growing gap in the frequency and size of new offerings compared to prior years. Some analysts…
Read More » -
Pfizer seeks full FDA approval of Paxlovid as questions about its benefits grow
A standard clearance could further broaden Paxlovid’s fast-rising use. But weaknesses are emerging too, among them unclear benefits in vaccinated people and a potential…
Read More » -
US pays Pfizer $3.2B to increase vaccine supply ahead of omicron booster push
The order will bolster the government stockpile of COVID-19 vaccines ahead of a booster rollout that the FDA now says…
Read More » -
FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects
Liver problems in trial volunteers led the agency to curtail studies of the drug, marking the second major setback related…
Read More »